anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To evaluate the predictive validity and cut-off point of heart rate and blood pressure on heart rate variability (HRV) changes in children with and without obesity.
METHODS: This study included 125 children, of whom 41 were normal weight and 84 were obese. Anthropometry, blood pressure, heart rate, and HRV were measured using an electronic scale and stadiometer, a sphygmomanometer, and HRV monitor. In addition, the receiver operating characteristic (ROC) curve was obtained by statistical analysis of the data.
RESULTS: Heart rate proved to be a good predictor for changes in the square root of the mean of the square of the differences between consecutive NN intervals (RMSSD) parameter in students of both sexes for the normal-weight group (ROC 0.89; 95%CI 0.77-1.00) and obesity (ROC 0.90; 95%CI 0.83-0.97). In addition, the heart rate cut-off point for alterations in the RMSSD parameter for normal-weight boys was 93 bpm (sensitivity 100.00% and specificity 87.50%) and for boys with obesity, the established cut-off point was 91 bpm (sensitivity 94.74% and specificity 63.64%). Heart rate also proved to be a good predictor considering low-frequency/high-frequency ratio (LF/HF) and standard deviation of long-term continuous NN intervals /standard deviation of the instantaneous variability of continuous NN intervals in the Poincaré graph ratio (SD2/SD1). Systolic and diastolic blood pressures were good predictors in more specific stratifications and, therefore, can be used in some cases.
CONCLUSIONS: The predictive validity of heart rate was shown to be at a good level, with high sensitivity and acceptable specificity for the cut-off points according to the different analyses stratified by gender and nutritional status. In this sense, health professionals will be able to use heart rate to estimate cardiovascular risk in children of different sexes and nutritional status.
The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults. Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times.
The present disclosure relates to apparatus designed to impregnate a sorbent. In some embodiments apparatus of the disclosure may comprise a mixing vessel having either a conical mixing chamber or an cylindrical mixing chamber designed to increase the contact surface area and/or contact/residence time of a sorbent and impregnant to produce compositions comprising an impregnated sorbent. Apparatus of the disclosure may also comprise one or more atomizers operable to produce atomized droplets of impregnant. The disclosure also provides methods for impregnation of a milled sorbent or an un-milled sorbent. Methods of the disclosure provide several technical advantages and may be cost effective. Impregnant sorbent compositions produced by methods and/or apparatus of the disclosure may have higher concentrations of an impregnant, a more uniform distribution of an impregnant and may have a greater sorbent efficiency.
BACKGROUND: Identifying children and adolescents with cardiometabolic risk at an early stage is crucial for effective treatment and prevention. From a practical perspective, this could be accomplished by assessing the presence of abdominal obesity, which serves as a surrogate indicator of increased cardiometabolic risk and is easy to measure. However, the assessment of abdominal obesity via waist circumference has not yet become a standard procedure in pediatric healthcare. The present study aimed to analyze the secular trends in increased cardiometabolic risk, as indicated by waist circumference among Spanish children and adolescents.
METHODS: This study included 4861 children and adolescents aged 8 to 16 years from two nationwide representative cross-sectional surveys, the EnKid study and the PASOS study, conducted in 1998-2000 and 2019-2020, respectively. Anthropometric variables were measured in both surveys by trained personnel. Three different waist-to-height (WHtR) cutoffs were used to define abdominal obesity as criteria for cardiometabolic risk. BMI categories were defined according to the IOTF and WHO growth charts.
RESULTS: Abdominal obesity [waist to height ratio (cm/cm) > 0.49] significantly increased from 40.7 to 56.1% and 93.8 to 97.2% in participants with overweight and obesity, respectively, between 1998-2000 and 2019-2020 (p < 0.05). Logistic regression analysis, adjusted for sex and age, revealed that the odds of being at increased cardiometabolic risk in 2019-2020 was 1.99 (95% CI 1.48-2.67) in participants with overweight in comparison with 1998-2000. The effect size was comparable among the three WHtR criteria for abdominal obesity or the BMI categories according to IOTF and WHO boundaries.
CONCLUSIONS: The prevalence of Spanish children with increased cardiometabolic risk, identified by abdominal obesity, significantly increased among those with overweight during the last two decades. This finding underlines the need of including the measurement of waist circumference as a standard procedure in pediatric practice.
Activated hepatic stellate cells differentiate into myofibroblasts, which synthesize and secrete extracellular matrix (ECM) leading to liver fibrosis. It was previously demonstrated that bulleyaconitine A (BLA), an alkaloid from Aconitum bulleyanum, inhibits proliferation and promotes apoptosis of human hepatic Lieming Xu-2 (LX-2) cells. In this study, we analyzed the effect of BLA on the production of ECM and related proteins by LX-2 cells activated with acetaldehyde (AA). The cells were randomized into the control group, AA group (cells activated with 400 μM AA), and BLA+AA group (cells cultured in the presence of 400 μM AA and 18.75 μg/ml BLA). In the BLA+AA group, the contents of collagens I and III and the expression of α-smooth muscle actin and transforming growth factor-β1 (TGF-β1) were statistically significantly higher than in the control, but lower than in the AA group. Expression of MMP-1 in the BLA+AA group was also significantly higher than in the AA group, but lower than in the control. Expression of TIMP-1 in the BLA+AA group was significantly higher than in the control, but lower than in the AA group. Thus, BLA suppressed activation and proliferation of LX-2 cells by inhibiting TGF-β1 signaling pathway and decreasing the content of collagens I and III by reducing the MMP-1/TIMP-1 ratio.
The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in "I" and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination (Posturarte® Olympic). To clean the participant's skin, cotton (MASMI®) will be passed with ethyl alcohol (Fergus®). Scissor (Maped®) will be used to cut the Kinesio Tape.
Patients with hardly resectable/unresectable limited metastasis in malignant melanoma stages IIIC/IV (AJCC 2010) carrying the BRAF V600 mutation, in order to achieve operability are enrolled in the NEO-VC-study. The main aim of this study is to achieve operability in a higher percentage of patients by neoadjuvant treatment through shrinkage of the tumors. Patients with operable stage IV disease show an impressive survival benefit with long term (5 y.) survival rates around 30 %. Only a percentage of up to 20 % can presently be treated by complete metastasectomy. This percentage may be enlarged by pre-treatment with an efficacious antitumor drug.
PURPOSE:To obtain an antiviral agent containing at least one kind of xylofuranan sulfate, ribopyranan sulfate, xylopyranan sulfate and ribofuranan sulfate. CONSTITUTION:At least one kind of xylofuranan sulfate, ribofuranan sulfate, xylopyranan sulfate, ribofuranan sulfate, derivative thereof and salt thereof is blended as an active ingredient and formulated according to a conventional method to provide the aimed product. Used amount thereof is 0.01-2000mg, preferably 0.02-500mg. The agent can be prepared to form of tablet, capsule, elixr, microcapsule or suspension agent. The agent is administered in dozes of 0.01-1000mg per patient several times and in total dozes of 0.02-2000mg daily. The antiviral agent is especially effective in AIDS virus and excellent anti-AIDS viral agent.
PROBLEM TO BE SOLVED: To obtain a hair-mother cell activator useful for preventing depilation and for growing the hair, containing, as active ingredient, a water extract from a specific kind of plant, and to obtain a hair growth stimulant composition formulated with the activator. SOLUTION: This hair-mother cell activator contains, as active ingredient, a water extract from scutellariae radix, a kind of plant belonging to Labiatae (e.g. a water crude extract from the plant, a purified fraction of the extract). The purified fraction is pref. a fraction <=13000 in a molecular weight cut off obtained by ultrafiltration of the above-mentioned crude extract, or a fraction 1000-3000 in molecular weight obtained by get filtration of the above fraction. The other objective hair growth stimulant composition contains the active ingredient at 0.001-10wt.% or so in terms of the water crude extract on a solid basis (0.001-10wt.% for the fraction <=13000 in molecular weight, 0.0001-1wt.% for the fraction 1000-3000 in molecular weight). This hair growth stimulant composition can be made into a formulation such as hair cream, hair lotion or hair tonic.
The group will receive treatment of therapeutic ultrasound. The US parameters will be programmed with a frequency of 1MHz, the intensity of 1.5 W/cm2, the Duty cycle of 100%, an ERA of 5cm2, and a time of 6 minutes. At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
BACKGROUD: Bronchopulmonary dysplasia (BPD) is one of the most important complications plaguing neonates and can lead to a variety of sequelae. the ability of the HIF-1α/VEGF signaling pathway to promote angiogenesis has an important role in neonatal lung development.
METHOD: Newborn rats were exposed to 85% oxygen. The effects of hyperoxia exposure on Pleomorphic Adenoma Gene like-2 (PLAGL2) and the HIF-1α/VEGF pathway in rats lung tissue were assessed through immunofluorescence and Western Blot analysis. In cell experiments, PLAGL2 was upregulated, and the effects of hyperoxia and PLAGL2 on cell viability were evaluated using scratch assays, CCK-8 assays, and EDU staining. The role of upregulated PLAGL2 in the HIF-1α/VEGF pathway was determined by Western Blot and RT-PCR. Apoptosis and ferroptosis effects were determined through flow cytometry and viability assays.
RESULTS: Compared with the control group, the expression levels of PLAGL2, HIF-1α, VEGF, and SPC in lung tissues after 3, 7, and 14 days of hyperoxia exposure were all decreased. Furthermore, hyperoxia also inhibited the proliferation and motility of type II alveolar epithelial cells (AECII) and induced apoptosis in AECII. Upregulation of PLAGL2 restored the proliferation and motility of AECII and suppressed cell apoptosis and ferroptosis, while the HIF-1α/VEGF signaling pathway was also revived.
CONCLUSIONS: We confirmed the positive role of PLAGL2 and HIF-1α/VEGF signaling pathway in promoting BPD in hyperoxia conditions, and provided a promising therapeutic targets.
Graphical layouts, algorithms, and methods are introduced herein to implement user interfaces for mobile and/or wearable medical devices. In one aspect of the present invention, new graphical layouts are introduced for simplified presentation of time-dependent patient data. In another aspect of the invention, methods and algorithms are introduced to acquire, extract and present relevant features of patient data in real-time in order to simplify the graphical presentation and interpretation. In another aspect of the invention, elements of a multi-modal user interface are introduced in order to simplify and minimize the user's interaction with the medical wearable device. In yet another aspect of the invention, further methods are introduced for real-time interaction between a user or several users and a wearable or several wearable medical devices. In one embodiment of the present invention, a smartphone, a smart watch, a head-mounted device or similar devices can be used to acquire and display in real-time patient data, e.g., electrocardiogram and relevant features, e.g., heart rate, etc. In another embodiment of the present invention, smartphones, smart watches, head-mounted devices or similar devices can be used to share in real-time the patient data.
Participants will receive a CST therapist call within 48 hours of randomization to discuss the study rationale, to conduct a relaxation exercise, and to review app and study logistics. Participants will use the Blueprint mobile app for 1 month.
ABSTRACT OF THE DISCLOSURE            The present invention is directed to naturally occurring and synthetic cytochalasin compositions and therapeutic treatments utilizing these compositions.  More specifically, the present invention relates to certain synthetic analogues of Cytochalasin B (CB) and sustained release formulations containing a cyctochalasin,  for example, cytochalasin B and other natural cytochalasins, for example, Cytochalasin D, E, H or J, among others and one or more of its synthetic analogues.  This invention also relates to the surprising discovery that the administration of cytochalasins including CB produces transient immunosuppression which is controllable by dose or route of administration and is reversible spontaneously or with the use of IL-2.  Thus, a therapeutic regimen of cytochalasins may be used to treat the undesirable hyperimmunity of transplant patients and patients with autoimmune disease.   In addition, anti-tumor therapy utilizing CB and other cytoshalasins,  and optionally antineoplastic agents other than cytochalasins may be signifantly enhanced by combining the administration of these agents with effective amounts of IL-2 or other lymphokines for reversing the immunosuppression produced during administration of cytochalasins with other antineoplastic agents.  This invention also relates to sustained release formulations utilizing liposomes of microcapsules which are effective for delivering high concentrations of cytochalasins and optionally, additional antineoplastic agents to the active site of the tumor without producing undesirable immunosuppression.
PURPOSE: A composition and a functional food containing an Aquilaria agallocha extract are provided to suppress excessive lipid generation, adipocyte differentiation, and fat accumulation, and to prevent and treat various diseases related to obesity and excessive lipid generation. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases selected from the group consisting of obesity, hyperlipidemia, and fatty liver contains an Aquilaria agallocha extract as an active ingredient. The extract is prepared from Aquilaria agallocha using a solvent selected from the group consisting of water, low carbon number alcohol, and a mixture thereof. The extract is Aquilaria agallocha oil which is prepared by distillation of Aquilaria agallocha with steam. Aquilaria agallocha is derived from Aquilaria plants. A functional food for preventing or treating diseases selected from the group consisting of obesity, hyperlipidemia, and fatty liver contains the extract as an active ingredient.
FIELD: medicine, oncology, medicinal genetics. SUBSTANCE: invention relates to somatic mutations in gene of multifunctional tumor suppressor (MTS) in the case human neoplasia and using these mutations for diagnosis and prognosis of oncological diseases. Invention relates to mutations of MTS gene in embryonic line and using these mutations for diagnosis of diathesis to the following cancer forms: melanoma, ocular melanoma, leukosis, astrocytoma, glyoblastoma, lymphoma, glyoma, Hodgkin's lymphoma, multiple myeloma, sarcoma, myosarcoma, cholangiosarcoma, squamous cell carcinoma, chronic lymphoid lympholeukosis and pancreas, ovary, uterine, testis, kidney, stomach, colon and straight intestine tumors also. Invention relates to also therapy of human neoplasia where mutation in MTS gene occurred including genetic therapy, substitution protein therapy and mimetics using. EFFECT: broadened arsenal of agents used for diagnosis and therapy of tumors. 53 cl, 9 tbl, 25 dwg
PURPOSE:The titled remedy, containing S-adenosyl-L-methionine as an active constituent, and administrable just after the fit without influence on the increasing action on blood stream nor the blood coagulation system regardless of the infarction nor hemorrhagic cerebral disorder. CONSTITUTION:A remedy for body dysfunction caused by cerebral disorder containing S-adenosyl-L-methionine (hereinafter abbreviated to SAM) as an active constituent. SAM is a physiologically active substance, and well-known as an antidepressant, analgesic and anti-inflammatory agent, etc. but found newly to have improved effect on recovery of dysfuntion caused by the cerebral disorder. The remedy is particularly usable just after the fit in cerebral infarction, intracranial hemorrhage, cerebral strain, etc. and is superior to the conventional chemotherapy. Usually, SAM is used in the form of a salt. Above, all, a complex salt of SAM with sulfuric acid or p-toluenesulfonic acid is preferred. SAM also has low toxicity.
The invention provides a gel preparation of compound kuh-seng lactic acid, which contains 1 to 10 percent of kuh-seng extract, 1 to 10 percent of lactic acid, 1 to 5 percent of hydroxyethyl cellulose and other alcohol substances. The invention also provides a preparation method of the gel preparation, which comprises the steps of using radix sophorae flavescentis extract; and (3) using hydroxyethyl cellulose as an excipient to form gel, dissolving the kuh-seng extract in lactic acid, ethanol and propylene glycol to form a solution, and adding the solution into the gel to finally prepare the compound kuh-seng gel preparation. Compared with other preparations such as gel, solution, lotion, ointment and the like, the gel preparation has the advantages of moderately controlling the pH environment in the vagina and forming a physiological environment suitable for the growth of lactobacillus in the vagina. Has the advantages of slow and sustained release of the drug effect in the vagina, long retention time of the active ingredients in the vagina, long duration of the drug effect and the like, thereby improving the drug effect. The compound kuh-seng lactic acid gel preparation provided by the invention can inhibit vaginal pathogenic bacteria when applied to vagina, is beneficial to growth of beneficial bacteria and restores vaginal flora balance. Maintains the normal physiological environment of the vagina, improves the resistance of the vagina, is nontoxic and nonirritant, is safe and effective, and has obvious curative effect.
Kidney transplantation remains the gold standard for patients with end-stage renal disease, but severe donor organ shortage has led to long waiting lists. The utilization of expanded criteria donor kidneys within the category of deceased donors has enlarged the pool of available kidneys for transplantation; however, these grafts often have an increased risk for delayed graft function or reduced graft survival following transplantation. During brain or circulatory death, neutrophils are recruited to the vascular beds of kidneys where a proinflammatory microenvironment might prime the formation of neutrophil extracellular traps (NETs), web-like structures, containing proteolytic enzymes, DNA, and histones. NETs are known to cause tissue damage and specifically endothelial damage while activating other systems such as coagulation and complement, contributing to tissue injury and an unfavorable prognosis in various diseases. In lung transplantation and kidney transplantation studies, NETs have also been associated with primary graft dysfunction or rejection. In this review, the role that NETs might play across the different phases of transplantation, already initiated in the donor, during preservation, and in the recipient, will be discussed. Based on current knowledge, NETs might be a promising therapeutic target to improve graft outcomes.
Therapeutic colloidal solns. of ferritin contain isotonic sea-water as the intermicellular liq., the ferritin comprising ferruginous micelles having a diameter of about 100 A charged with electricity and magnetism, at a dosage corresponding to the treatment required. The amt. of iron present is about 1 part per 1000, but may be less. The magnetic charge is generally 180 gauss, magnetic satn. of these sols. being 200 gauss. Used for treatment of cancer and leukemia, arterial and cardiac disorders, brain tumours and aneurism, and neurological disorders. They are also useful as anti-radiation agents and prevent disorders due to weightlessness.
Graphene oxide (GO), a carbon-based material with oxygen-containing functional groups, can be applied in biomedicine for drug delivery, cancer therapy, and tissue regeneration. We have previously shown that nanoscale-sized graphene oxide (NGO), an oxidized graphene derivative, exhibits effective anti-inflammatory activity in a murine model of sepsis mediated by T helper (Th)1-promoting cytokines such as IFNγ and TNFα. However, whether NGO influences Th2-induced skin inflammation remains unclear. To address this issue, we employed an ovalbumin (OVA) plus aluminum hydroxide (Alum)-induced Th2-mediated skin inflammation model in conjunction with OVA-specific DO11.10 T cell receptor transgenic Balb/c mice. In vivo NGO injection upon OVA/Alum sensitization down-regulated OVA-elicited antigen-specific Th2 cells and GATA3-expressing Th2-type regulatory T cells. Next, we examined the effect of NGO injection on OVA/Alum-induced atopic dermatitis (AD)-like skin inflammation. NGO-injected mice exhibited significantly decreased Th2 disease phenotypes (e.g., a lower clinical score, decreased epidermal thickness and Th2 cell differentiation, and fewer infiltrated mast cells and basophils in skin lesions) compared with vehicle-injected control mice. Overall, our results suggest that NGOs are promising therapeutic materials for treating allergic diseases such as AD.
The investigators included all hospitalisations for LPN using CCAM(Classification Commune des actes médicaux) code (JAFC005) after removing the 83 hospitals using RAPN in 2017. LPN complications were from hospitals using exclusively LPN.
Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
New recombinant DNA (I) comprises the cDNA of foot and mouth disease (serotype 0), having homopolymeric cytidyl sequence (polyC-region) as an insert in pFMDV-YEP-polyC. Included are variants of (I) which differ only within the scope of natural varitions of the virus. Also new are plasmids (replicable in procaryotic and/or eucaryotic cells) contg. (I) under control of an RNA-polymerase promoter. USE/ADVANTAGE - (I), for plasmids contg. it, are used to produce infectious, virulent or attenuated foot and mouth disease viruses (FMDV) (a) by transcription to RNA which is isolated then used to transfect permissive cells or (b), by direct transfection of cells. The infectious virus particles (which can be of any serotype) produced are useful (opt. after chemical inactivation) for making vaccines to protect animals against FMDV infections.